CORNOVUS PHARMACEUTICALS INC.

Cornovus Pharmaceuticals Inc. is a specialized pharmaceutical contractor focused on the research, development, and regulatory support of novel therapeutic compounds. Based in Farmington, Connecticut, the company leverages deep expertise in drug formulation, preclinical pharmacology, and Good Laboratory Practice (GLP) compliance to advance early-stage pipeline candidates through investigational new drug (IND) enablers. Their technical capabilities include analytical method validation, bioanalytical assay development, and toxicology study design, with an emphasis on small molecule and biologic candidates targeting chronic and rare diseases. The firm’s differentiation lies in its integrated approach to translational science, bridging laboratory innovation with FDA submission readiness through robust data package construction and quality systems aligned with 21 CFR Part 11 and ICH guidelines. No award history is available to infer specific agency engagements, and therefore no consistent patterns of federal partnership can be identified. Similarly, no NAICS codes or contract volume data are provided to define primary industry verticals or market positioning. The company’s operational scope remains centered on pharmaceutical R&D services, though without public contract records, its exact client base or federal program alignment cannot be determined. Cornovus Pharmaceuticals Inc. operates as a small, privately held entity (2L structure) with no publicly disclosed government certifications. Its geographic footprint is localized to Connecticut, suggesting a lean, science-driven team focused on contract research rather than large-scale manufacturing or distribution. The company positions itself within the biopharmaceutical services sector, offering specialized support to sponsors navigating the complexities of preclinical development and regulatory submission pathways.